Vivos Therapeutics Shares Surge After $4.5 Million Debt Conversion Fuels Nasdaq Optimism
Vivos shares soared nearly 36% after a debt-to-equity swap deal with Streeterville Capital aimed at restoring Nasdaq compliance, but the transaction hinges on new equity financing, leaving dilution and delisting risks unresolved.